نتائج البحث

Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period

• Authors : Samah Hayek; Joseph Levy; Galit Shaham

Subjects: COVID-19; Effectiveness; Monoclonal antibodies

• Source: Infect Dis TherInfectious Diseases and Therapy, Vol 14, Iss 2, Pp 433-445 (2025)

تفاصيل العنوان

Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups

• Authors : Samah Hayek; Joseph Levy; Galit Shaham

Subjects: Real-world evidence; 0301 basic medicine; 03 medical and health sciences

• Source: Infect Dis TherInfectious Diseases and Therapy, Vol 13, Iss 6, Pp 1379-1389 (2024)

تفاصيل العنوان

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

• Authors : Kijak, GH; Ahani, B; Arbetter, D

Subjects: Tixagevimab; Cilgavimab; COVID-19

• Source: Infect Dis TherInfectious Diseases and Therapy, Vol 12, Iss 12, Pp 2691-2707 (2023)

تفاصيل العنوان

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (TRUST)

• Source: Open-Label, Uncontrolled, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 Weeks

تفاصيل العنوان

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

• Authors : Hobbs, FDR; Montgomery, H; Padilla, F

Subjects: Hospitalization; SARS-CoV-2; Symptoms

• Source: Infect Dis TherInfectious Diseases and Therapy, Vol 12, Iss 9, Pp 2269-2287 (2023)

تفاصيل العنوان

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

• Authors : International Network for Strategic Initiatives in Global HIV Trials (INSIGHT); University of Copenhagen; Medical Research Council

• Source: A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H4:

تفاصيل العنوان

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

• Authors : Iqvia Pty Ltd

• Source: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two

تفاصيل العنوان

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials

• Authors : Myron J. Levin; Andrew Ustianowski; Stephane De Wit

Subjects: Monoclonal antibody; 0301 basic medicine; 0303 health sciences

• Source: Infect Dis TherInfectious Diseases and Therapy, Vol 13, Iss 6, Pp 1253-1268 (2024)

تفاصيل العنوان

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

• Source: Phase 1, Randomized, Open Label, Three-arm, Single Dose, Parallel Group Study to Compare AZD7442 (AZD8895 + AZD1061) Pharmacokinetic Exposure Following Intramuscular

تفاصيل العنوان

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 (ENDURE)

• Source: A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics

تفاصيل العنوان